Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Clinical trial NCT06364423 · RECRUITING

Trial details

NCT number: NCT06364423
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Leukemia, Lymphocytic, Chronic, B-Cell B-Lymphocytic Leukemia, Chronic B-Cell Chronic Lymphocytic Leukemia Acute Lymphoblastic Leukemia Lymphoblastic Lymphoma Leukemia, Acute Lymphoblastic Small Lymphocytic Lymphoma

Start date: 2024-09-03
Primary completion: 2029-07-01
Enrollment: 132

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.